Clinical Trials Directory

Trials / Terminated

TerminatedNCT00410150

Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation

A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Children's Hospital Medical Center, Cincinnati · Academic / Other
Sex
All
Age
24 Months – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate whether heliox-powered albuterol nebulizer therapy will result in reduced inpatient length of stay in children hospitalized with acute asthma exacerbations.

Detailed description

We hypothesize that heliox-powered albuterol nebulizer therapy will result in reduced inpatient length of stay in children hospitalized with acute asthma exacerbations. Severity of asthma will be characterized using a modified Becker Clinical Asthma Score (CAS) based upon the acuity of physical signs for four clinical characteristics (respiratory rate, wheezing, I/E ratio, and accessory muscle use). Scoring will occur at the time of enrollment and every 4 hours thereafter until the patient meets hospital discharge criteria. All scoring using the CAS will be performed by an independent physician, nurse or respiratory therapist blinded to the subject treatment arm. All children will receive standard cardiopulmonary monitoring and treatment, consisting of supplemental oxygen delivered as needed by either nasal cannula or face mask to maintain oxygen saturation \>90%, maintenance intravenous fluids, corticosteroid therapy and nebulized albuterol therapy. After written informed consent, eligible children will be randomized to one of two study groups using a sealed envelope technique: Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 70:30 Heliox. Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments, including continuous therapy, powered by 100% oxygen per usual standard of care.

Conditions

Interventions

TypeNameDescription
DRUGHelium-oxygen-driven albuterol nebulizerSubjects will be treated with continuous albuterol nebs with Heliox
DRUGOxygenSubjects will be treated with continuous albuterol nebs in oxygen

Timeline

Start date
2006-04-01
Primary completion
2007-12-01
Completion
2007-12-01
First posted
2006-12-12
Last updated
2010-11-08
Results posted
2010-10-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00410150. Inclusion in this directory is not an endorsement.